Latest News

Here's some of what is coming soon to NeurologyLive® this week.

A new cross-sectional study found that professional identity partially explains the connection between burnout and missed nursing care among neuro-oncology nurses in China, with psychological capital buffering both pathways.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is chronobiology in neurology!

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 31, 2026.

Updated phase 2 data showed durable responses and sustained disease control with safusidenib after nearly 40 months of follow-up, prompting plans for phase 3 and phase 2 studies in newly diagnosed and post-vorasidenib IDH1-mutant glioma.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with neuro-oncologist Na Tosha Gatson, MD, PhD, FAAN. [LISTEN TIME: 20 minutes]

Experts discuss how plasma biomarkers may enable earlier detection of Alzheimer disease pathology, including in cognitively unimpaired individuals and those with subjective cognitive decline, while offering a more accessible alternative to CSF and PET-based assessment. [WATCH TIME: 8 Minutes]

The nonbinding vote casts doubt on the therapy's path to approval ahead of an August 22 FDA decision, capping over a year of regulatory back-and-forth over the strength of its phase 3 data.

Stephanie Fradette, PharmD, senior vice president and head of Rare Neurology Department Unit at Biogen, gave commentary on the FDA designation and long-term outlook for salanersen, an investigational antisense agent for spinal muscular atrophy.

Carrie Hersh, DO, MSc, FAAN, president of the Consortium of Multiple Sclerosis Centers, discussed key sessions presented on disability progression, emerging biomarkers, and the shift toward comprehensive, patient-centered MS care.

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, talked about the need to rethink multiple sclerosis clinical trial design by recognizing immune cells’ potential neuroprotective roles.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.